With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Also in today’s newsletter, Trump sanctions Chinese companies over Iran oil shipments, and Foxconn set to sign contract to ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.

Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs have transformed the way we think about our bodies, weight loss, and wellness. Ozempic and other GLP-1 drugs like it ...